Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.

Biotechnology

Education

Lucy Therapeutics

Lucy Therapeutics' headquarters in Cambridge, MA, United States

Amy Ripka

Allen Hopper

Bryan Keaney

Ann DeWitt

John Ripple

Joanne Bronson

Peter Lansbury

Giovanni Manfredi

John Macor

Nelli Mnatsakanyan

David Rotella

Laurie Sanders

James Summers

Description

People (4)

Amy Ripka

John Ripple

Ann DeWitt

Allen Hopper

Jobs